In 2025, growth was significantly higher than in the previous two years at seven percent. The data is based on the leading 20 biopharma companies by R&D spending. The rate of return decreased significantly in 2022.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Deloitte. (April 24, 2026). Rate of return on the biopharmaceutical late-stage R&D pipeline from 2013 to 2025 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 23, 2026, from /statistics/886479/projected-randd-investment-returns-us-biopharma/
Deloitte. "Rate of return on the biopharmaceutical late-stage R&D pipeline from 2013 to 2025." Chart. April 24, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 23, 2026. /statistics/886479/projected-randd-investment-returns-us-biopharma/
Deloitte. (2026). Rate of return on the biopharmaceutical late-stage R&D pipeline from 2013 to 2025. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 23, 2026. /statistics/886479/projected-randd-investment-returns-us-biopharma/
Deloitte. "Rate of Return on The Biopharmaceutical Late-stage R&d Pipeline from 2013 to 2025." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 Apr 2026, /statistics/886479/projected-randd-investment-returns-us-biopharma/
Deloitte, Rate of return on the biopharmaceutical late-stage R&D pipeline from 2013 to 2025 ÌÇÐÄÆƽâ°æ, /statistics/886479/projected-randd-investment-returns-us-biopharma/ (last visited July 23, 2026)
Rate of return on the biopharmaceutical late-stage R&D pipeline from 2013 to 2025 [Graph], Deloitte, April 24, 2026. [Online]. Available: /statistics/886479/projected-randd-investment-returns-us-biopharma/
